NIH Translational Research for Rare Diseases and Orphan Products: NCGC and TRND
|
|
- Paul Bond
- 6 years ago
- Views:
Transcription
1 NIH Translational Research for Rare Diseases and Orphan Products: NCGC and TRND Christopher P. Austin, M.D. Director, NIH Chemical Genomics Center Senior Advisor to the NHGRI Director for Translational Research National Institutes of Health IOM Commmittee on Accelerating Rare Diseases Research and Orphan Product Development February 4, 2010
2 The Problem Basic Research Drugs The Opportunity Drugs Basic Research
3 The best of times, the worst of times How to translate the genome into biological insights and therapeutics?
4 The Problem of Rare and Neglected Diseases ~7,000 diseases affect humankind Only a very small fraction of diseases support commercial development of therapeutic agents Two types of neglected diseases: Low prevalence, i.e., rare Prevalence <200,000 in USA There are >6000 rare (orphan) diseases Cumulative prevalence in U.S. ~ million Most are single gene diseases; e.g., cystic fibrosis, Huntington disease, sickle cell disease, Tay-Sachs Approximately 200 have any pharmacotherapy available from the 340 products approved by FDA High prevalence but neglected Occur chiefly among impoverished and marginalized populations in developing nations who are unable to afford treatments Most are infectious diseases, e.g., malaria, schistosomiasis, leishmaniasis, trypanosomiasis
5 Only a small % of diseases and genome-encoded targets are being addressed for drug development Current drug targets: Well understood proteins Current diseases: Prevalent diseases that affect developed world Neglected Neglected Human Genome Human Diseases
6 Conventional roles of NIH and biopharma in drug development NIH- Funded Basic Science Pharma and Biotech FDA Dedicated Chem-Biol Project Team formed Compound accepted into Clinical Development Indefinite 1 yr 1 yr 1 yr ~ 3 yrs 1 yr 2 yrs ~3 yrs 1.5 yrs Indefinite Screening (HTS or otherwise) Target identification Assay development Hit-to- Probe Lead Development, Optimization Ph I Ph II Clinical Trials Ph III Regulatory review Ph IV-V (Additional indications, Safety monitoring)
7 To empower the research community to use small molecule compounds in their research, whether as tools to perturb genes and pathways, or as starting points to the development of new therapeutics for human disease.
8 The Molecular Libraries Roadmap Compounds Repository Diversity expansion Assays Development Screening solicitation Instrumentation Development Data and Chemical Probe Generation Screening/Informatics Chemistry/Pharmacology Comprehensive Centers Specialized Centers Specialized Centers Data Probes Data Dissemination/Analysis PubChem MLPCN Centers
9
10 The Molecular Libraries Probe Production Network (MLPCN) Comprehensive Centers Specialized Screening Centers Specialized Chemistry Centers University of Kansas Specialized Chemistry Center Broad Institute Comprehensive Screening Center The Johns Hopkins Ion Channel Center NIH Chemical Genomics Center (NCGC) San Diego Center for Chemical Genomics (Burnham Institute) The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development New Mexico Molecular Discovery Center Scripps Research Institute Molecular Screening Center Southern Research Specialized Biocontainment Center
11 NIH Chemical Genomics Center Founded as part of Roadmap 75 scientists > 100 collaborations with investigators worldwide 75% NIH extramural 15% Foundations, Research Consortia, Pharma/Biotech 10% NIH intramural Focus on novel targets, rare/neglected diseases Produces chemical probes/leads new paradigms for assay development, screening, informatics, chemistry
12 NCGC Staff Informatics, 7 Scientific and Admin Management, 6 Lab Operations, 2 Automation and Cmd Mgt, 6 Chemistry, 15 Assay Development and Biology, 18
13 NCGC Operation Assay Investigator Peer review Advice Optimize Assay Compound Repository YES NO Meets probe criteria? Candidate Probe NCGC Chemical Genomics Browser Optimization Chemistry Bioassay Screen Data
14 LTS MTS HTS 10 s/day 1000 s/day 10,000 s/day 100,000 s/day Throughput Molecular mechanism Immediate organismal relevance
15 NCGC Screening Collections MLSMR DC = Diversity Compounds NC = Non-commercial TL-KIN = Kinase Targeted Library TL-GPCR = GPCR Targeted Library TL-IC = Ion Channel Targeted Library TL-PRO = Protease Targeted Library TL-NUC = Nuclear Receptor Targeted TL-NTP = National Toxicology Program SS = Known Bioactives NP = Natural Products DEA = DEA Controlled Substances
16 NCGC Screening System 1: BSL1/Kalypsys Capacity: 3.0MM Assay Wells 5.0MM Compound Wells Throughput: Readers: New Capabilities: 1400 plates/day ViewLux (2) Acumen (2) Envision (2) Automatic Loading and Unloading stations using commercially available plate stackers Dispense Inspection Systems using integrated CCD cameras
17 NCGC Screening System 2: BSL2/HRE Capacity: Throughput: Readers: New Capabilities: 370K Assay Wells 370K Compound Wells ~240 plates/day ViewLux Acumen Hamamatsu Modular approach to HTS Three docking stations to quickly facilitate changing of both compound and assay plate storage Flexible scheduling software to allow for complex assay methods BSL2 rated to further diversify the assays capable of being run by NCGC
18 NCGC Screening System 3: BSL3/Beckman
19 Disease areas of NCGC assays Metabolic Diseases 5% Genetic Diseases 5% Other 5% Toxicology 7% Basic Research 36% Neuroscience 8% Infectious Diseases 11% Cancer 23%
20 Trans-NIH nature of Molecular Libraries Roadmap brings about synergies Tdp1 NCGC has projects on many aspects of DNA repair from different areas of science Yossi Shiloh, Tel Aviv University ATM (Neurology, cancer) Yves Pommier, NCI Tdp1 (Cancer) David Wilson, NIA Ape1 (Aging) Roger Woodgate, NICHD DNA Pol ε, ι (Development) Sam Wilson, NIEHS DNA Pol β (Environmental toxicology) Shunichi Takeda, Kyoto University XRCC1 (Aging, toxicology) Structural Genomics Consortium RecQ1 helicase (Basic research) Bloom helicase (Cancer)
21 NCGC Chemical Genomics Browser
22 Rare/neglected disease projects at NCGC Ataxia-telangiectasia Beta-thalassemia Charcot-Marie-Tooth Chordoma Chronic lymphocytic leukemia Gaucher disease Huntington s disease Leishmaniasis Lymphangioleiomyomatosis Malaria Myotonic dystrophy Niemann-Pick C Progeria Schistosomiasis Spinal muscular atrophy Trypanosomiasis
23 NCGC Drug Repurposing Program Approved drugs have safety/efficacy in at least one other disease Repurposing leapfrogs most stages of drug development, thereby offering potentially rapid therapeutic advance Pharmacology of drugs identified may confer insights into disease pathophysiology NCGC has assembled comprehensive approved drugs collection Working with large number of disease foundations to leverage this collection for rare diseases Cuts out medchem optimization but many issues remain Dose and administration different (e.g., acute v. chronic)? Formulation different? BBB penetration? Tox studies appropriate? Clinical population similar? If not, studies needed
24 Two approaches to therapeutics for rare and neglected diseases 1-2 years? >400,000 compounds, 10 yrs Target Screen Hit Lead Lead Optimization Preclinical Development Clinical Trials FDA approval 3000 drugs
25 NCGC Pharmaceutical Collection Status May 2009 Drug Source In house Need to procure Total US FDA UK/EU/Canada/Japan INN Total Approved Total Informatics sources for NPC US FDA: Orange Book, OTC, NDC, Green Book, Drugs at FDA Britain NHS EMEA Health Canada Japan NHI Physical sources for NPC Procurement from >20 suppliers worldwide In-house purification of APIs from marketed forms Synthesis
26 NPC Niemann-Pick Disease Type C Collaboration with Denny Porter (NICHD/NIH), Bill Pavan (NHGRI/NIH), Dan Ory (Wash U) Autosomal recessive disease Prevalence: 1:150,000 Clinical manifestations: progressive neurodegeneration, hepatosplenomegaly, death by teens Characterized by a lysosomal accumulation of unesterified cholesterol and other lipids. Mutated genes: NPC1 (95%) and NPC2 (5%) Purpose of project: utilize patient cells and approved drug collection to repurpose an existing drug for NPC
27 Filipin(Blue) Cell Mask (Red) NPC Corrector identified from screening of NCGC Pharmaceutical Collection Reduction in Free Cholesterol Accumulation and Lysosome Size 50 um 25 um 12.5 um 6.25 um DMSO Lysotracker (Red) Hoescht(Blue) Reduction in Cholesterol Accumulation (cholesterol oxidase assay) Normalized ATP Level GM [Compound], mm DMSO Normalized Cholesterol Level Normalized ATP Level NPC [Compound], mm 3.9 DMSO Normalized Cholesterol Level Normalized ATP Level WT (5659) [Compound], mm DMSO Normalized Cholesterol Level ATP (2 d) ATP (4 d) ATP (6 d) Cholesterol (2 d) Cholesterol (4 d) Cholesterol (6 d)
28 Ameliorating the Defect in Gaucher s Disease NCGC Collaboration with Ellen Sidransky, NHGRI Gaucher s Disease Rare disease caused by mutations in enzyme glucocerebrosidase (GCS) u glucosylceramide Current treatment: enzyme replacement Limited efficacy, no BBB penetration, expensive Many mutations are missense, leading to trafficking defect Pharmacological chaperones a therapeutic possibility Fluorogenic substrate assay: v Resorufin β-d-glucopyranoside Cerebrosidase + Resorufin Ex 570 nm / Em 590 nm Glucose
29
30 Developing drugs for Schistosomiasis Livers of treated mice Ex vivo worm killing
31 Inhibitors of Schistosoma mansoni TGR NCGC Collaboration with David Williams Department of Immunology and Microbiology Rush University Medical Center Chicago, IL
32 Discovery of Pathway: 2002 Identification of Target: 2006
33 Quantitative HTS: ,000 compounds at 7 concentrations (qhts) Dose-response curve for all compounds (PNAS 103, (2006)) ~10,000,000 data points (16 Time-Point Reads) 31 hours of robot time Results: 100 compounds with IC50 < 40 µm 71 compounds 6 different structural classes
34 Series Expansion & Target ID PhosphinicAmide S O P N HN R1 O P HN R1 Oxadiazole2-oxide R 1 R 2 N O - N O Isoxazolone O N Br O R 1 Analogue# R 1 qhts R N O O O EtO F O MeO O O O S S N N -CN O O Cl N N S OEt O O OMe O O O NA NA NA NA O -Ph NA NA NA O N N S O Confirmation TGR Assay NS NS >57 >57 >50 NS ND ND > NS NS All retested compounds were found to be inactive against Prx2, leaving TGR as the sole target for all confirmed actives. Singleton hits 3, 10 and 14 were confirmed and successfully expanded to small series. The top active compounds were highly potent, with IC 50 s approaching the limit of detection. Phosphoramidite O HN NH P O O R chlorophenyl NA 14 naphthyl NA 15 phenyl NA 16 4-ethoxyphenyl NA NS NS NS Simeonov et al, PLoS Negl. Trop. Dis., 2, e107 (2008).
35 Chemical probes: 2008
36 In vivo validation of mechanism: 2008 Livers of treated mice Ex vivo killing of S. mansoni worms by NCGC1597 S. mansoni-infected mice treated with 10 mg/kg IP for 5 days
37 Probes are just the start of drug development Cumulative Cost Probability of success Public Sector Science Pre-MLI Dedicated Chem-Biol Project Team formed Compound accepted into Clinical Development Indefinite 1 yr 1 yr 1 yr ~ 3 yrs 1 yr 2 yrs ~3 yrs 1.5 yrs Indefinite Screening (HTS or otherwise) Target identification Assay development Hit-to- Probe Lead Development, Optimization Ph I Ph II Clinical Trials Ph III Regulatory review Ph IV-V (Additional indications, Safety monitoring)
38 Probes are just the start of drug development Cumulative Cost Probability of success Public Sector Science with MLI Dedicated Chem-Biol Project Team formed Compound accepted into Clinical Development Indefinite 1 yr 1 yr 1 yr ~ 3 yrs 1 yr 2 yrs ~3 yrs 1.5 yrs Indefinite Screening (HTS or otherwise) Target identification Assay development Hit-to- Probe Lead Development, Optimization Ph I (Safety) Ph II (Dose finding, initial efficacy in patient pop.) Ph III (Efficacy and safety in large populations) Regulatory review Ph IV-V (Additional indications, Safety monitoring)
39 TRND program will bring compounds to point of clinical testing/commercial adoption Basic Research NCGC, Molecular Libraries Initiative TRND (RAID) Biotech, Pharma NIH Clinical Center CTSAs FDA IND Indefinite 1 yr 1 yr 1 yr 2 yrs 2 yrs 1 yr 2 yrs ~3 yrs 1 yr Indefinite Target identification Assay HTS development Hit-to- Probe Probe Lead Candidate PK/PD In vivo Tox Formulation GMP Manufacture Ph I (Safety) Ph II (Dose finding, initial efficacy in patient pop.) Ph III (Efficacy and safety in large populations) Regulatory review Ph IV-V (Additional indications, Safety monitoring)
40
41 Analogous to NCGC TRND Operational Model In-house laboratories with expertise in preclinical drug development will collaborate with external laboratories with expertise in disease/target Projects will be taken to phase needed for external organization to adopt for clinical development Projects will enter TRND at a variety of stages of development Distinguishing features Disease agnostic, will look explicitly for cross-cutting mechanisms Processes will be established to incorporate learning from each project to operationalize continuous improvement Science of preclinical drug development Reasons for successes and failures will be investigated and published
42 Administered by NHGRI TRND Science Starting point: Chemical probe End point: Clinical candidate compound attractive for adoption by biotech/pharma Project-specific activities Medicinal chemistry in vitro efficacy, pharmacology, ADME, toxicology in vivo drug metabolism, pharmacokinetics/pharmacodynamics, toxicology Compound scale-up Technology/paradigm development At least 20% of effort to improving success rates
43 TRND Operations Initial plan, assuming $24 M per year, is to work on approximately five projects per year The average project should take approximately two years Projects will be monitored closely for progress; those making insufficient headway will be culled quickly, to allow next project in pipeline to start as soon as possible Anticipated timeline FY09: infrastructure FY10: governance, hiring, research community outreach, 2-3 pilot projects to establish operational processes FY11: solicitation of projects for adoption, 4-5 projects ongoing FY12: fully operational
44 TRND Governance (working) Centered at Office Of Rare Diseases Research Takes advantage of ORDR s inherently pan-ic nature and long-standing relationships with rare disease community Active involvement and representation of ICs and community Trans-NIH Staff Advisory Group Advise on operation Help integrate TRND with related NIH efforts Expert External Panel From academia, industry, and patient advocacy communities Helps select projects Assesses progress in an ongoing manner Performs formal periodic assessments and recommendations regarding TRND
45 TRND: Project Selection (working) Projects will be solicited from extramural and intramural researchers, foundations, and biotechs/pharmas Will look for targets, pathways, mechanisms that could apply to >1 disease (e.g., lysosomal storage diseases, diseases of DNA repair) First-level review will be performed by the External Expert Panel Second-level review will be performed by the Trans-NIH Advisory Group Stay tuned
46 TRND is interacting with many different groups in planning activities US Government NIH Institutes and centers Intramural including CC Extramural» funded researchers» programs including CTSA, CTEP, RAID, NBS research network Office of Tech Transfer Office of General Counsel FDA including CDER and OOPD Centers for Disease Control and Prevention Office of Science and Technology Policy Non-US government Biotech and pharma companies VC organizations Rare disease foundations Neglected disease organizations Advocacy groups
47 Questions?
Drug Discovery and Development at NIH for Rare and Neglected Diseases September 29, 2009
Drug Discovery and Development at NIH for Rare and Neglected Diseases September 29, 2009 Melissa Ashlock, Christopher P. Austin, Steve Groft Genetic Alliance Posted in the Resource Repository at: http://www.resourcerepository.org/documents/1692/drugdiscoveryanddevelopmentat
More informationCompeting & Collaborating to Achieve Successful Drug Repositioning
Competing & Collaborating to Achieve Successful Drug Repositioning Noel Southall, Ph.D. National Human Genome Research Institute National Institutes of Health July 14, 2011 NIH Chemical Genomics Center
More informationThe Impact of Genomics on Drug Development, Clinical Research, and Medical Practice
The Impact of Genomics on Drug Development, Clinical Research, and Medical Practice Christopher P. Austin. M.D. Senior Advisor to the Director for Translational Research National Human Genome Research
More informationDrug Repurposing at NCATS
Drug Repurposing at NCATS JOHN C. MCKEW, PH.D. ACTING SCIENTIFIC DIRECTOR, DIVISION OF PRE-CLINICAL INNOVATION, NCATS JUNE 24, 2013 IOM GENOMICS-ENABLED DRUG RPEPURPOSING AND REPOSITIONING TRND: Therapeutics
More informationDisruptive Innovation at the NIH. Kathy Hudson, Ph.D. Deputy Director Science, Outreach, and Policy National Institutes of Health
Disruptive Innovation at the NIH Kathy Hudson, Ph.D. Deputy Director Science, Outreach, and Policy National Institutes of Health NIH: Steward of Medical and Behavioral Research for the Nation Science in
More informationLili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences
Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences (NCATS), NIH GUIRR Meeting, October 9, 2012 Established
More informationNIH Introduction to the Principles and Practice of Clinical Research February 28, 2012
The Impact of Genomics on Clinical Research and Drug Development Christopher P. Austin. M.D. Scientific Director, NIH Center for Translational Therapeutics Director, Division of Preclinical Innovation
More informationNIH-RAID: A ROADMAP Program
NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationIntegration of FDSS7000 into a modular robotic system for Open Innovation drug discovery
Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery José Manuel Brea & María Isabel Loza BioFarma, Santiago de Compostela DRUG DISCOVERY OPEN INNOVATION CLOSED innovation
More informationINTRODUCTION TO DRUG DISCOVERY
INTRODUCTION TO DRUG DISCOVERY AND ITS FUNDING including the Alabama Drug Discovery Alliance Maaike Everts, PhD Associate Director Topics to Cover The Drug Discovery and Development Pipeline Funding Opportunities
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationChristopher P. Austin, M.D. NCATS Director IQ Symposium December 5, 2012
Christopher P. Austin, M.D. NCATS Director IQ Symposium December 5, 2012 Basic Laboratory Research Clinical Research Improved Public Health Translational Research Population Research Basic Laboratory Research
More informationPresentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development
Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International
More informationCollaborative Rare Diseases Research Activities at NIH
Collaborative Rare Diseases Research Activities at NIH Christopher P. Austin, M.D. Director National Center for Advancing Translational Sciences IRDiRC April 16, 2013 Background ~ 18 25 million people
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationIntroduction to Drug Design and Discovery
Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,
More informationDiscovery of a First-In-Class Topically Bioavailable Kit Inhibitor With Clinical Activity Using Computational Chemogenomics Technology
20131009-03 Discovery of a First-In-Class Topically Bioavailable Kit Inhibitor With Clinical Activity Using Computational Chemogenomics Technology James Hendrix, Ph.D. President - Technology Med Chem &
More informationRare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
More informationDHODH: StructureGuided Design of a. New Class of Drugs. Defeating Malaria Together. Meg Phillips, Ph.D. UT Southwestern
DHODH: StructureGuided Design of a New Class of Drugs Defeating Malaria Together Meg Phillips, Ph.D. UT Southwestern 1 Pipeline to development of a DHODH-based anti-malarial 2001 Phillips enzymology/ structure/hts;
More information- Selection of Target Molecular for Drug Discovery by Verifications on the Validity of Target Candidates -
University of Tokyo and Astellas Enter Collaborative Research for Target Discovery of New Drugs for Neglected Tropical Diseases Caused by Protozoan Parasites - Selection of Target Molecular for Drug Discovery
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationImpurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA
Overview of exploratory INDs Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT Office of New Drugs Center for Drug Evaluation
More informationRecent years have witnessed an expansion in the disciplines encompassing drug
Course overview Recent years have witnessed an expansion in the disciplines encompassing drug discovery outside the pharmaceutical industry. This is most notable with a significant number of Universities
More informationLessons from the Human Genome Project that may be applicable to the Exposome Endeavor
Lessons from the Human Genome Project that may be applicable to the Exposome Endeavor Christopher P. Austin. M.D. Director, NIH Chemical Genomics Center Senior Advisor to the NHGRI Director for Translational
More informationMAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT
MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT PharmaSUG Single Day Event Using Standards, Even for Non-Standard
More informationImpact of Collaborative Robots at The Genomics Institute of the Novartis Research Foundation (GNF) Dan Sipes Novartis Foundation
Impact of Collaborative Robots at The Genomics Institute of the Novartis Research Foundation (GNF) Dan Sipes Novartis Foundation Outline What is GNF? Approach How it works The need for collaborative robots
More informationCHAPTER 4. Milestones of the drug discovery
CHAPTER 4 Milestones of the drug discovery 4.Milestones of the drug discovery: Highlights the importance of the below critical milestones of the drug discovery and correlated to the current research. 1.
More informationThe Power to Cure: Therapeutic Innovation in Academia
The Power to Cure: Therapeutic Innovation in Academia Leslie Molony, Ph.D. November 7, 2011 Sanford-Burnham Medical Research Institute: a Non Profit Basic Research Institute Santa Barbara Est. 2006 La
More informationDrug Targets - an overview of historical success and protein kinase inhibitors - successes and attrition. John P. Overington
Drug Targets - an overview of historical success and protein kinase inhibitors - successes and attrition John P. Overington jpo@ebi.ac.uk Assay/Target ChEMBL The Organisation of Drug Discovery 1. Scientific
More informationResources for the Microbiology and Infectious Diseases Research Community
Resources for the Microbiology and Infectious Diseases Research Community Martin John Rogers, PhD Program Officer, Parasitology and International Programs Division of Microbiology and Infectious Diseases
More informationThe Right Molecules. Designed. Delivered.
The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered
More informationCharacterization of Niemann-Pick Type C mutant mice using automated cage monitoring systems
Characterization of Niemann-Pick Type C mutant mice using automated cage monitoring systems Dr. Sangeetha V. Iyer Perlara PBC San Francisco, CA sangeetha@perlara.com Contents Introduction to Perlara PBC
More informationFinancial Results FY2018 Q3
Financial Results FY2018 Q3 (January to September 2018) Carna Biosciences, Inc. Stock Code:4572 1 FY2018 Q3 Key Highlights Established the clinical development team to initiate clinical trials of Carnaʼs
More informationUniversity of Pennsylvania Perelman School of Medicine High Throughput Screening Core
University of Pennsylvania Perelman School of Medicine High Throughput Screening Core Sara Cherry, Ph. D. David C. Schultz, Ph. D. dschultz@mail.med.upenn.edu (215) 573 9641 67 John Morgan Building Mission
More informationIn Vitro Pharmacology Services
In Vitro Pharmacology Services Simplify Your Drug Discovery Workflow What s What s Inside: Inside: Why DiscoverX Services x GPCR Screening & Profiling x Kinase Screening & Profiling x Safety Screening
More informationNatural Products and Drug Discovery
Natural Products and Drug Discovery Secondary metabolism Building blocks & Phytochemicals Drug discovery 26-Oct-18 2 Secondary metabolism: Biochemical reactions derived from primary metabolic pathways
More informationChristopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013
Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013 Basic Laboratory Research Clinical Research Improved Public Health Translational Research Population Research Basic
More informationTranslational Research through Public-Private Partnerships. 65 th Annual Bohan Lecture. Scott J. Weir, PharmD, PhD 08 October 2011
Translational Research through Public-Private Partnerships 65 th Annual Bohan Lecture Scott J. Weir, PharmD, PhD 08 October 2011 Drug Focused Translational Research Translational Research Defined by the
More informationJefferies Global Health Care Conference. June 1, 2015
Jefferies Global Health Care Conference June 1, 2015 Forward-Looking Statements This presentation may contain projections, estimates and other forwardlooking statements that involve a number of risks and
More informationOrgans on Chips: The Future of Translational Research
Organs on Chips: The Future of Translational Research KRISTIN FABRE, PHD SCIENTIFIC PROGRAM MANAGER NIH NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCE (NCATS) 1 Advancing regulatory sciences Drug
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationLaura Andrews, PhD, DABT, Fellow ATS
Laura Andrews, PhD, DABT, Fellow ATS What is a Biologic? From PHS Act of 1944 A biologic is any virus, toxin, antitoxin, therapeutic serum, vaccine, blood, blood component or derivative, allergenic products
More informationBioFarma USEF. Expertise in drug discovery projects
BioFarma USEF Expertise in drug discovery projects Since more than 15 years, we have provided custom assay development, compound profiling, high-throughput screening services and collaborations in over
More informationEXPERT COLLECTION. Explore our leading medical review series
EXPERT COLLECTION Explore our leading medical review series Introducing the EXPERT COLLECTION The Taylor & Francis Expert Collection is the world s largest series of review journals in research, development,
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationSuccessful Academia-Pharma Collaboration Drug Discovery and Clinical Development
Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development Toshio MIYATA Tohoku University Graduate School of Medicine United Centers for Advanced Research and Translational Medicine
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationUnlocking protein production with translational read-through for rare genetic diseases. Investor Presentation February 2018
Unlocking protein production with translational read-through for rare genetic diseases Investor Presentation February 2018 1 Forward-Looking Statements Certain statements included in this presentation
More informationThe National Institutes of Health ICs: mission and funding strategies
The National Institutes of Health ICs: mission and funding strategies Perry Kirkham, Ph.D. Office of the Vice President for Research E-mail: pkirkham@purdue.edu Phone: 63645 NIH Workshop topics and dates
More informationCompound Re-Profiling. Dr Robert Scoffin CEO, Cresset
Compound Re-Profiling Dr Robert Scoffin CEO, Cresset What is it? F F F N N H 2 N S O O Br > Compound Re-Profiling or Re-Purposing is the process of finding a new clinical use for an existing treatment
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationCareful Transition. Getting into Business (Science) in Hungary. Janos Nacsa MD, PhD
Careful Transition Getting into Business (Science) in Hungary Janos Nacsa MD, PhD Zoltan Szallasi MD internationally renowned scientist in bioinformatics and system biology, specializing on how various
More informationInnovative Strategies to Accelerate Academic Drug Discovery. Vincent Groppi, Ph.D Director Center for the Discovery of New Medicines
Innovative Strategies to Accelerate Academic Drug Discovery Vincent Groppi, Ph.D Director Center for the Discovery of New Medicines 9 out of 10 Drugs Fail Hay, Thomas, Craighead, Economides & Rosenthal.
More informationCareer Growth Areas in Physiology / Pharmacology
Career Growth Areas in Physiology / Pharmacology Magdalena Alonso-Galicia, PhD Pharmacology Department Forest Research Institute, Inc. Jersey City, NJ 1 Career Growth Areas in BioPharma n Pharmaceutical
More informationUNLEASH THE POWER OF PRECISION MEDICINE
FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery. www.dcb.org.tw The Center for Biotechnology With over 400 dedicated researchers and
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More informationLA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES
LA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES Francesca Pasinelli Direttore Generale 3 Congresso Nazionale SIFaCT Roma, 9 ottobre 2015 About Telethon Fondazione Telethon is
More informationProgress and Future Directions in Integrated Systems Toxicology. Mary McBride Agilent Technologies
Progress and Future Directions in Integrated Systems Toxicology Mary McBride Agilent Technologies 1 Toxicity testing tools of the late 20 th century Patchwork approach to testing dates back to the 1930
More informationOVERVIEW OF DRUG INNOVATION TO COMMERCIALIZATION
Kaur et al Journal of Drug Delivery & Therapeutics; 2014, 4(5), 36-43 36 Available online on 15.09.2014 at http://jddtonline.info Journal of Drug Delivery and Therapeutics Open access to Pharmaceutical
More informationUniversity of California Center for Accelerated Innovation
University of California Center for Accelerated Innovation MICHAEL PALAZZOLO April 6, 2015 Outline CAI overview and introduction RFA and important dates Selection process Pre-application Finding help 2
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationStem Cell Research: Identifying emerging high priority policy issues
The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November
More informationDuncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline
R&D Strategy Bridging g the academia-industry industry yg gap Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline GSK at a glance Who we are We are a science-led global healthcare
More informationContent Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA )
Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA ) Area 1.0 Basic Biomedical Sciences (10%) Area 2.0 Pharmaceutical Sciences (33%) Area 3.0 Social/Behavioral/Administrative Sciences (22%)
More informationCentre for Drug Design and Discovery CD3. Centre for Drug Design and Discovery
Centre for Drug Design and Discovery 3 Centre for Drug Design and Discovery The investment fund for innovative small molecule academic drug discovery" 16 June 2010 UCL - Sopartec 3? THE CENTRE FOR DRUG
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationFRDA CLINICAL TRIALS. Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center. Meeting
FRDA CLINICAL TRIALS Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center US STUDIES FUNDED BY FARA, MDA, NAF, AND NIH FOR FA 18 16 14 12 10 8 6 4 2 0 1997 1998 1999 2000 2001 2002
More informationFrom Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager
From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationToxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development
Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA
More informationRobert J. Beall, PhD, President and Chief Executive Officer Cystic Fibrosis Foundation
Name and Organization: Robert J. Beall, PhD, President and Chief Executive Officer Cystic Fibrosis Foundation Subject of Testimony: Food and Drug Administration Funding for Fiscal Year 2013 Point of Contact:
More informationInnovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
More informationAgreed with W. Cornell Graduate Program and Tri-I
Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration
More informationA unique Collaborative Model for the Discovery of New Therapeutic Approaches
A unique Collaborative Model for the Discovery of New Therapeutic Approaches THE INNOVATION GAP OPEN INNOVATION TO ADDRESS THE LACK OF PRODUCTIVITY OF BIOPHARMACEUTICAL RESEARCH A PRE-COMPETITIVE PHARMA
More informationPharma Research Revolution in Drug Discovery
Pharma Research Revolution in Drug Discovery Wolfgang Hartwig Head of Research, Pharmaceuticals Business Group Life Science Revolution at the Turn of the Millennium 1992: Robotic screening 1999: New organs
More informationFundación. Discovering the Future
Fundación Discovering the Future November 2013 About us Independent, Non-profit Research rganization established as a Privatepublic partnership between Government of Andalucía (Spain) University of Granada
More informationMissouri Regional Life Sciences Summit March 9, 2010 The Institute for Advancing Medical Innovation Stepping into the future of drug discovery, delivery and biomedical engineering G. Sitta Sittampalam,
More informationThe Integrated Biomedical Sciences Graduate Program
The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to
More informationNEWSLETTER MAY To Our Shareholders:
NEWSLETTER MAY 2017 To Our Shareholders: I appreciate your interest in the work done by NeOnc Technologies, Inc. (NTI) and your continued trust. I want to update you on the progress of our activities in
More informationDuchenne Muscular Dystrophy
Duchenne Muscular Dystrophy Clinical and Commercial Strategy Dr. Leslie Hudson, President and CEO September 10, 2008 Duchenne Muscular Dystrophy (DMD) Defects in the dystrophin gene; no protein expression
More informationGreen
Green BioPharma @Genentech Tse-Sung Wu, PhD May 2013 tsesung@gene.com Outline 2 Genentech Backgrounder Definition of Green BioPharma Green Chemistry at Genentech Organizational Change Model Strategic Focus
More informationNIEHS and Data Integration
NIEHS and Data Integration Where We ve Been and Where We re Going Linda Birnbaum, Ph.D., D.A.B.T., A.T.S. Director National Institute of Environmental Health Sciences National Toxicology Program Informing
More informationNon-Dilutive Funding for Opportunities for CNS/PNS Related R&D
FreeMindGroup FreeMind Group @FreeMindGrp Non-Dilutive Funding for Opportunities for CNS/PNS Related R&D Jonathan H. Adalist Sr. Director, Business Development September 6, 2017 FreeMind Group FreeMind
More informationDRUG DISCOVERY AND DEVELOPMENT-PRECLINICAL ASPECTS
DRUG DISCOVERY AND DEVELOPMENT-PRECLINICAL ASPECTS 4th November 2014 Biomedicine Masters Program, Lund University Wayne Russell, PhD. ZEALAND PHARMA AGENDA TODAYS TALK: - INTRODUCTION TO DRUG DISCOVERY
More informationKey Activities. Ofer Reizes, Ph.D. Skills Development Director
Key Activities Ofer Reizes, Ph.D. Skills Development Director 1 Key Activities Core Question: What key activities required for your Value Propositions? Key Partners Key Activities Key Resources Value Proposition
More informationKRISANI BIO SCIENCES PVT. LTD.
KRISANI BIO SCIENCES PVT. LTD. Flat B2, 2 nd Floor, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad, Telangana 500078. Email: kkr@krisanibio.com. URL: www.krisanibio.com Contact Number: +91 98494
More informationChemoinformatic Tools for the Hit Discovery Process
Chemoinformatic Tools for the Hit Discovery Process GmbH Björn Windshügel May 29 2013 ESP in a Nutshell Established in 2007 Service provider for academics High-throughput screening High-content screening
More informationAcquisition of Vtesse Inc. Increased Focus on Orphan and Pediatric Diseases
Acquisition of Vtesse Inc. Increased Focus on Orphan and Pediatric Diseases 1 Forward Looking Statement This presentation contains "forward-looking statements" as that term is defined in the Private Securities
More informationEARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS
EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS As a full service contract research organisation performing phase I to IV clinical trials across Europe and the Americas for 40
More informationDennis Wright, Ph.D. Professor of Medicinal Chemistry NPDD Initiative UCONN School of Pharmacy University of Connecticut
Craig M. Crews, Ph.D. Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology Chemistry, Pharmacology Center for Molecular Discovery Yale University Dennis Wright, Ph.D. Professor
More informationOn behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic
Robert J. Beall, Ph.D. President and Chief Executive Officer Cystic Fibrosis Foundation On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic fibrosis (CF) in the United States,
More informationOverview and Status Update
T H E S C R I P P S R E S E A R C H I N S T I T U T E S C R I P P S F L O R I D A T H E S C R I P P S R E S E A R C H I N S T I T U T E Scripps Florida Overview and Status Update 7 November 2011 Harry
More informationThe Role of the NIH Clinical Center in Translational and Clinical Research
The Role of the NIH Clinical Center in Translational and Clinical Research International Conference on Engineering Science and Technology 2014 John I. Gallin, M.D. Director, NIH Clinical Center Associate
More informationNIAID Resources to Facilitate Medical Countermeasure Development
NIAID Resources to Facilitate Medical Countermeasure Development Paula Bryant, Ph.D. Senior Scientific Officer Concept Acceleration Program Biodefense, Research Resources, and Translational Research (OBRRTR)
More informationFDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer
FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer Yongjie Zhou, M.D., Ph.D. FDA/CBER/OCTGT/DCEPT Yongjie.zhou@fda.hhs.gov isbtc Global Regulatory Summit October 29, 2008
More informationLili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences
Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences (NCATS), NIH Email: Lili.Portilla@nih.gov Established
More informationReal World Drug Discovery A Chemist's Guide to Biotech and Pharmaceutical Research
Real World Drug Discovery A Chemist's Guide to Biotech and Pharmaceutical Research Robert M. Rydzewski ELSEVIER Amsterdam Boston Heidelberg London New York Oxford Paris San Diego San Francisco Singapore
More information